You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIndacaterol
Accession NumberDB05039
TypeSmall Molecule
GroupsApproved
DescriptionIndacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Structure
Thumb
Synonyms
5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one
QAB 149
QAB-149
QAB149
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arcapta NeohalerCapsule75 ug/1Oral; Respiratory (inhalation)Novartis Pharmaceuticals Corporation2011-07-01Not applicableUs
Hirobriz BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Hirobriz BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd2009-11-30Not applicableEu
Onbrez BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Onbrez BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Onbrez BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Onbrez BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Onbrez BreezhalerCapsule75 mcgRespiratory (inhalation)Novartis Pharmaceuticals Canada Inc2012-03-05Not applicableCanada
Onbrez BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Onbrez BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Onbrez BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Onbrez BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Onbrez BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Onbrez BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.2009-11-30Not applicableEu
Oslif BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerCapsule300 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Oslif BreezhalerCapsule150 μgRespiratory (inhalation)Novartis Europharm Ltd.  2009-11-30Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Arcapta Novartis
HirobrizNot Available
OnbrezNovartis
Onbrize Not Available
Brand mixtures
NameLabellerIngredients
Ultibro BreezhalerNovartis Pharmaceuticals Canada Inc
Utibron NeohalerNovartis Pharmaceuticals Corporation
Salts
Name/CASStructureProperties
Indacaterol Maleate
753498-25-8
Thumb
  • InChI Key: IREJFXIHXRZFER-PCBAQXHCSA-N
  • Monoisotopic Mass: 508.220951388
  • Average Mass: 508.5629
DBSALT000101
Categories
UNII8OR09251MQ
CAS number312753-06-3
WeightAverage: 392.4907
Monoisotopic: 392.209992772
Chemical FormulaC24H28N2O3
InChI KeyQZZUEBNBZAPZLX-QFIPXVFZSA-N
InChI
InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1
IUPAC Name
5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one
SMILES
CCC1=C(CC)C=C2CC(CC2=C1)NC[[email protected]](O)C1=C2C=CC(=O)NC2=C(O)C=C1
Pharmacology
IndicationFor the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Structured Indications
PharmacodynamicsBronchodilator drugs are the foundation for the treatment of chronic obstructive pulmonary disease. The principal inhaled bronchodilator treatments used are β(2) -agonists and anticholinergics, either alone or in combination. Currently available β(2) -agonists are of either short duration and used multiple times/day, or of long duration, which requires twice-daily administration. Indacaterol is considered an ultra-long-acting β(2) -agonist and was recently approved for use in the United States. Its duration of action is approximately 24 hours, allowing for once-daily administration. Furthermore, this chiral compound it is given as the R-enantiomer and acts as a full agonist. Cough was the most commonly reported adverse effect with use of indacaterol. Compared to salmeterol, it has 35% more agonist activity. Cough usually occurred within 15 seconds of inhalation of the drug, lasted around 6 seconds, was not associated with bronchospasm, and did not cause discontinuation of the drug. Otherwise, the drug's safety profile was similar to that of other bronchodilators. [PMID: 22499359]
Mechanism of actionIndacaterol works by stimulating adrenergic beta-2 receptors in the smooth muscle of the airways. This causes relaxation of the muscle, thereby increasing the diameter of the airways, which become constricted in asthma and COPD. It is also long acting due to its high affinity to the lipid raft domains in the airway membrane so it slowly dissociates from the receptors. Indacaterol also has a high intrinsic efficacy so it is also very rapid acting - onset of action occurs within 5 minutes. The pharmacological effects of beta2-adrenoceptor agonist drugs, including indacaterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3’, 5’-adenosine monophosphate (cyclic monophosphate). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle. In vitro studies have shown that indacaterol has more than 24-fold greater agonist activity at beta2-receptors compared to beta1-receptors and 20-fold greater agonist activity compared to beta3-receptors. This selectivity profile is similar to formoterol. The clinical significance of these findings is unknown.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-2 adrenergic receptorProteinyes
agonist
HumanP07550 details
Related Articles
AbsorptionThe median time to reach peak serum concentrations of indacaterol was approximately 15 minutes after single or repeated inhaled doses. Absolute bioavailability of indacaterol after an inhaled dose was on average 43-45%.
Volume of distribution

After intravenous infusion the volume of distribution (Vz) of indacaterol was 2,361 L to 2,557 L indicating an extensive distribution.

Protein bindingThe in vitro human serum and plasma protein binding was 94.1-95.3% and 95.1-96.2%, respectively.
Metabolism

After oral administration of radiolabeled indacaterol, unchanged indacaterol was the main component in serum, accounting for about one third of total drug-related AUC over 24 hours. The monohydroxylated derivative, glucuronide conjugate, and the 8-O-glucuronide were the most prominent metabolites in serum. Other metabolites identified include a diastereomer of the hydroxylated derivative, a N-glucuronide of indacaterol, and C- and N-dealkylated products. In vitro investigations indicated that UGT1A1 was the only UGT isoform that metabolized indacaterol to the phenolic O-glucuronide. CYP3A4 is the predominant isoenzyme responsible for hydroxylation of indacaterol.

SubstrateEnzymesProduct
Indacaterol
Not Available
8-O-glucuronideDetails
Route of eliminationRenal clearance plays a minor role (about 2 to 6% of systemic clearance) in the elimination of systemically available indacaterol. In a human ADME study where indacaterol was given orally, the fecal route of excretion was dominant over the urinary route. Indacaterol was excreted into human feces primarily as unchanged parent drug (54% of the dose) and, to a lesser extent, hydroxylated indacaterol metabolites (23% of the dose).
Half lifeIndacaterol serum concentrations declined in a multi-phasic manner with an average terminal half-life ranging from 45.5 to 126 hours. The effective half-life, calculated from the accumulation of indacaterol after repeated dosing with once daily doses between 75 mcg and 600 mcg ranged from 40 to 56 hours which is consistent with the observed time-to-steady state of approximately 12-15 days.
Clearance

Renal clearance of indacaterol is, on average, between 0.46 and 1.2 L/h. Serum clearance of indacaterol is 18.8 L/h to 23.3 L/h.

ToxicityThe expected signs and symptoms associated with overdosage of indacaterol are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., angina, hypertension or hypotension, tachycardia, with rates up to 200 bpm, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of indacaterol.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneIndacaterol may increase the hypokalemic activities of 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneIndacaterol may increase the hypokalemic activities of 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneIndacaterol may increase the hypokalemic activities of 4-Androstenedione.Experimental, Illicit
5-androstenedioneIndacaterol may increase the hypokalemic activities of 5-androstenedione.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Indacaterol.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Indacaterol.Approved
AcetaminophenThe serum concentration of Indacaterol can be increased when it is combined with Acetaminophen.Approved
AfatinibThe serum concentration of Indacaterol can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Indacaterol can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneIndacaterol may increase the hypokalemic activities of Alclometasone.Approved
AldosteroneIndacaterol may increase the hypokalemic activities of Aldosterone.Experimental
AlectinibThe serum concentration of Indacaterol can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Indacaterol can be increased when it is combined with Alfentanil.Approved, Illicit
AlprenololAlprenolol may decrease the bronchodilatory activities of Indacaterol.Approved, Withdrawn
AmantadineThe serum concentration of Indacaterol can be increased when it is combined with Amantadine.Approved
Ambroxol acefyllinateThe risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Indacaterol.Experimental
AmcinonideIndacaterol may increase the hypokalemic activities of Amcinonide.Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Indacaterol.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Indacaterol can be increased when it is combined with Aminohippuric acid.Approved
AminophyllineThe risk or severity of adverse effects can be increased when Aminophylline is combined with Indacaterol.Approved
AmiodaroneThe metabolism of Indacaterol can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Indacaterol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Indacaterol can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Indacaterol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Indacaterol can be increased when it is combined with Amsacrine.Approved
AnagrelideIndacaterol may increase the QTc-prolonging activities of Anagrelide.Approved
AnecortaveIndacaterol may increase the hypokalemic activities of Anecortave.Investigational
AprepitantThe serum concentration of Indacaterol can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideIndacaterol may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherIndacaterol may increase the QTc-prolonging activities of Artemether.Approved
AsenapineIndacaterol may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Indacaterol can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Indacaterol can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Indacaterol can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the tachycardic activities of Indacaterol.Approved
AtorvastatinThe serum concentration of Indacaterol can be increased when it is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Indacaterol is combined with Atosiban.Approved
AzelastineThe serum concentration of Indacaterol can be increased when it is combined with Azelastine.Approved
AzithromycinIndacaterol may increase the QTc-prolonging activities of Azithromycin.Approved
BeclomethasoneIndacaterol may increase the hypokalemic activities of Beclomethasone.Investigational
Beclomethasone dipropionateIndacaterol may increase the hypokalemic activities of Beclomethasone dipropionate.Approved, Investigational
BedaquilineIndacaterol may increase the QTc-prolonging activities of Bedaquiline.Approved
BendroflumethiazideIndacaterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Indacaterol.Withdrawn
BenzocaineThe serum concentration of Indacaterol can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Indacaterol can be increased when it is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Betahistine.Approved
BetamethasoneIndacaterol may increase the hypokalemic activities of Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Indacaterol.Approved
BexaroteneThe serum concentration of Indacaterol can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Indacaterol can be increased when it is combined with Biperiden.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Indacaterol.Approved
BoceprevirThe metabolism of Indacaterol can be decreased when combined with Boceprevir.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Indacaterol.Approved
BortezomibThe metabolism of Indacaterol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Indacaterol can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Indacaterol can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Indacaterol can be increased when it is combined with Bromocriptine.Approved, Investigational
BudesonideIndacaterol may increase the hypokalemic activities of Budesonide.Approved
BumetanideIndacaterol may increase the hypokalemic activities of Bumetanide.Approved
BupranololBupranolol may decrease the bronchodilatory activities of Indacaterol.Approved
BuprenorphineThe serum concentration of Indacaterol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Indacaterol can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Indacaterol can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Indacaterol.Approved
CanagliflozinThe serum concentration of Indacaterol can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Indacaterol can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Indacaterol can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Indacaterol can be increased when combined with Carbamazepine.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Indacaterol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Indacaterol.Approved
CarvedilolThe serum concentration of Indacaterol can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Indacaterol can be increased when it is combined with Caspofungin.Approved
CeliprololCeliprolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
CeritinibThe serum concentration of Indacaterol can be increased when it is combined with Ceritinib.Approved
ChloroquineIndacaterol may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideIndacaterol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineIndacaterol may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Indacaterol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Indacaterol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneIndacaterol may increase the hypokalemic activities of Chlorthalidone.Approved
CholesterolThe serum concentration of Indacaterol can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Indacaterol can be decreased when it is combined with Cholic Acid.Approved
CiclesonideIndacaterol may increase the hypokalemic activities of Ciclesonide.Approved, Investigational
CilazaprilThe serum concentration of Indacaterol can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Indacaterol can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinIndacaterol may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideIndacaterol may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramIndacaterol may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Indacaterol can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Indacaterol can be decreased when combined with Clemastine.Approved
ClobetasolIndacaterol may increase the hypokalemic activities of Clobetasol.Investigational
Clobetasol propionateIndacaterol may increase the hypokalemic activities of Clobetasol propionate.Approved
ClocortoloneIndacaterol may increase the hypokalemic activities of Clocortolone.Approved
ClofazimineThe serum concentration of Indacaterol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Indacaterol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Indacaterol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineIndacaterol may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe metabolism of Indacaterol can be decreased when combined with Cobicistat.Approved
ColchicineThe serum concentration of Indacaterol can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Indacaterol can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Indacaterol can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateIndacaterol may increase the hypokalemic activities of Cortisone acetate.Approved
CrizotinibIndacaterol may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indacaterol.Approved
CyclophosphamideThe serum concentration of Indacaterol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Indacaterol can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Indacaterol can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Indacaterol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Indacaterol can be increased when it is combined with Dactinomycin.Approved
DarunavirThe metabolism of Indacaterol can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Indacaterol can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Indacaterol can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Indacaterol can be decreased when it is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateIndacaterol may increase the hypokalemic activities of dehydroepiandrosterone sulfate.Investigational
DelavirdineThe metabolism of Indacaterol can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Indacaterol can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Indacaterol can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneIndacaterol may increase the hypokalemic activities of Desoximetasone.Approved
Desoxycorticosterone acetateIndacaterol may increase the hypokalemic activities of Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateIndacaterol may increase the hypokalemic activities of Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneIndacaterol may increase the hypokalemic activities of Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateIndacaterol may increase the hypokalemic activities of Dexamethasone isonicotinate.Vet Approved
DextromethorphanThe serum concentration of Indacaterol can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Indacaterol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiflorasoneIndacaterol may increase the hypokalemic activities of Diflorasone.Approved
DifluocortoloneIndacaterol may increase the hypokalemic activities of Difluocortolone.Approved
DifluprednateIndacaterol may increase the hypokalemic activities of Difluprednate.Approved
DigoxinThe serum concentration of Indacaterol can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Indacaterol can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Indacaterol can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Indacaterol can be increased when it is combined with Dipyridamole.Approved
DisopyramideIndacaterol may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideIndacaterol may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronIndacaterol may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneIndacaterol may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Indacaterol.Approved
DoxazosinThe serum concentration of Indacaterol can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Indacaterol can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Indacaterol can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Indacaterol can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Indacaterol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneIndacaterol may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolIndacaterol may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DyphyllineThe risk or severity of adverse effects can be increased when Dyphylline is combined with Indacaterol.Approved
EfavirenzThe serum concentration of Indacaterol can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Indacaterol can be increased when it is combined with Elbasvir.Approved
EliglustatIndacaterol may increase the QTc-prolonging activities of Eliglustat.Approved
EnalaprilThe serum concentration of Indacaterol can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Indacaterol can be decreased when it is combined with Enzalutamide.Approved
EquileninIndacaterol may increase the hypokalemic activities of Equilenin.Experimental
EquilinIndacaterol may increase the hypokalemic activities of Equilin.Approved
ErgonovineThe serum concentration of Indacaterol can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Indacaterol can be increased when it is combined with Ergotamine.Approved
ErythromycinIndacaterol may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramIndacaterol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Indacaterol can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Indacaterol.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Indacaterol.Approved
EstramustineThe serum concentration of Indacaterol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Indacaterol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneIndacaterol may increase the hypokalemic activities of Estrone.Approved
Estrone sulfateIndacaterol may increase the hypokalemic activities of Estrone sulfate.Approved
Etacrynic acidIndacaterol may increase the hypokalemic activities of Etacrynic acid.Approved
EtoposideThe serum concentration of Indacaterol can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Indacaterol can be decreased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Indacaterol can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Indacaterol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Indacaterol can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Indacaterol can be increased when it is combined with Fidaxomicin.Approved
FlecainideIndacaterol may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
fluasteroneIndacaterol may increase the hypokalemic activities of fluasterone.Investigational
FluconazoleThe metabolism of Indacaterol can be decreased when combined with Fluconazole.Approved
FludrocortisoneIndacaterol may increase the hypokalemic activities of Fludrocortisone.Approved
FlumethasoneIndacaterol may increase the hypokalemic activities of Flumethasone.Approved, Vet Approved
FlunisolideIndacaterol may increase the hypokalemic activities of Flunisolide.Approved, Investigational
Fluocinolone AcetonideIndacaterol may increase the hypokalemic activities of Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideIndacaterol may increase the hypokalemic activities of Fluocinonide.Approved, Investigational
FluocortoloneIndacaterol may increase the hypokalemic activities of Fluocortolone.Approved, Withdrawn
FluorometholoneIndacaterol may increase the hypokalemic activities of Fluorometholone.Approved
FluoxetineIndacaterol may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolIndacaterol may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Indacaterol can be increased when it is combined with Fluphenazine.Approved
FluprednideneIndacaterol may increase the hypokalemic activities of Fluprednidene.Approved, Withdrawn
FluprednisoloneIndacaterol may increase the hypokalemic activities of Fluprednisolone.Approved
FlurandrenolideIndacaterol may increase the hypokalemic activities of Flurandrenolide.Approved
FlurazepamThe serum concentration of Indacaterol can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateIndacaterol may increase the hypokalemic activities of Fluticasone furoate.Approved
Fluticasone PropionateIndacaterol may increase the hypokalemic activities of Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Indacaterol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneIndacaterol may increase the hypokalemic activities of Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Indacaterol can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Indacaterol can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Indacaterol can be increased when combined with Fosphenytoin.Approved
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Indacaterol.Approved, Vet Approved
FurosemideIndacaterol may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Indacaterol can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidIndacaterol may increase the QTc-prolonging activities of Gadobenic acid.Approved
GefitinibThe serum concentration of Indacaterol can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinIndacaterol may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Indacaterol can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Indacaterol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Indacaterol can be increased when it is combined with Glycerol.Experimental
GoserelinIndacaterol may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Indacaterol can be increased when it is combined with Gramicidin D.Approved
GranisetronIndacaterol may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinThe serum concentration of Indacaterol can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolIndacaterol may increase the QTc-prolonging activities of Haloperidol.Approved
HE3286Indacaterol may increase the hypokalemic activities of HE3286.Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Indacaterol.Approved
HydrochlorothiazideIndacaterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneIndacaterol may increase the hypokalemic activities of Hydrocortisone.Approved, Vet Approved
HydroflumethiazideIndacaterol may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbutilideIndacaterol may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Indacaterol can be increased when it is combined with Idelalisib.Approved
IloperidoneIndacaterol may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Indacaterol can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Indacaterol can be increased when it is combined with Imipramine.Approved
IndapamideIndacaterol may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Indacaterol can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indacaterol can be increased when it is combined with Indomethacin.Approved, Investigational
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Indacaterol.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Indacaterol.Withdrawn
IsavuconazoniumThe metabolism of Indacaterol can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Indacaterol.Approved
IsradipineThe metabolism of Indacaterol can be decreased when combined with Isradipine.Approved
IstaroximeIndacaterol may increase the hypokalemic activities of Istaroxime.Investigational
ItraconazoleThe metabolism of Indacaterol can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Indacaterol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Indacaterol can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Indacaterol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Indacaterol can be decreased when combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Indacaterol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Indacaterol can be increased when it is combined with Lapatinib.Approved, Investigational
LenvatinibIndacaterol may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideIndacaterol may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinIndacaterol may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Indacaterol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Indacaterol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Indacaterol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Indacaterol can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Indacaterol can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Indacaterol can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Indacaterol can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Indacaterol can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Indacaterol can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Indacaterol can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Indacaterol can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Indacaterol is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Indacaterol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Indacaterol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineIndacaterol may increase the QTc-prolonging activities of Lumefantrine.Approved
MaprotilineThe serum concentration of Indacaterol can be increased when it is combined with Maprotiline.Approved
ME-609Indacaterol may increase the hypokalemic activities of ME-609.Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Indacaterol.Withdrawn
MebendazoleThe serum concentration of Indacaterol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MedrysoneIndacaterol may increase the hypokalemic activities of Medrysone.Approved
MefloquineThe serum concentration of Indacaterol can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Indacaterol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelengestrolIndacaterol may increase the hypokalemic activities of Melengestrol.Vet Approved
MeprobamateThe serum concentration of Indacaterol can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneIndacaterol may increase the QTc-prolonging activities of Methadone.Approved
MethyclothiazideIndacaterol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Indacaterol.Investigational
MethylprednisoloneIndacaterol may increase the hypokalemic activities of Methylprednisolone.Approved, Vet Approved
MetolazoneIndacaterol may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe serum concentration of Indacaterol can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Indacaterol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Indacaterol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Indacaterol can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Indacaterol.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Indacaterol.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Indacaterol.Approved
MitomycinThe serum concentration of Indacaterol can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Indacaterol can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Indacaterol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Indacaterol.Approved
ModafinilThe serum concentration of Indacaterol can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneIndacaterol may increase the hypokalemic activities of Mometasone.Approved, Vet Approved
MorphineThe serum concentration of Indacaterol can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinIndacaterol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Indacaterol.Approved
NafcillinThe serum concentration of Indacaterol can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Indacaterol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Indacaterol can be increased when it is combined with Naringenin.Experimental
NCX 1022Indacaterol may increase the hypokalemic activities of NCX 1022.Investigational
NebivololNebivolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
NefazodoneThe metabolism of Indacaterol can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Indacaterol can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Indacaterol can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Indacaterol can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Indacaterol can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Indacaterol.Withdrawn
NicardipineThe serum concentration of Indacaterol can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Indacaterol can be decreased when it is combined with Nifedipine.Approved
NilotinibIndacaterol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Indacaterol can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Indacaterol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Indacaterol can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Indacaterol can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Indacaterol.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Indacaterol.Withdrawn
OfloxacinIndacaterol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe metabolism of Indacaterol can be decreased when combined with Olaparib.Approved
Oleoyl estroneIndacaterol may increase the hypokalemic activities of Oleoyl estrone.Investigational
OmeprazoleThe serum concentration of Indacaterol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronIndacaterol may increase the QTc-prolonging activities of Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Indacaterol.Investigational
OsimertinibThe serum concentration of Indacaterol can be increased when it is combined with Osimertinib.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Indacaterol.Approved
P-NitrophenolThe serum concentration of Indacaterol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Indacaterol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Indacaterol can be increased when it is combined with Palbociclib.Approved
PaliperidoneIndacaterol may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Indacaterol can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatIndacaterol may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Indacaterol can be increased when it is combined with Pantoprazole.Approved
ParamethasoneIndacaterol may increase the hypokalemic activities of Paramethasone.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Indacaterol.Approved
ParoxetineThe serum concentration of Indacaterol can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibIndacaterol may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
PentamidineIndacaterol may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe metabolism of Indacaterol can be increased when combined with Pentobarbital.Approved, Vet Approved
PerflutrenIndacaterol may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe serum concentration of Indacaterol can be increased when it is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Indacaterol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Indacaterol.Withdrawn
PhenobarbitalThe metabolism of Indacaterol can be increased when combined with Phenobarbital.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Indacaterol.Withdrawn
PhenytoinThe metabolism of Indacaterol can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideIndacaterol may increase the QTc-prolonging activities of Pimozide.Approved
PindololPindolol may decrease the bronchodilatory activities of Indacaterol.Approved
PiretanideIndacaterol may increase the hypokalemic activities of Piretanide.Experimental
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Indacaterol.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Indacaterol.Withdrawn
Platelet Activating FactorThe serum concentration of Indacaterol can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideIndacaterol may increase the hypokalemic activities of Polythiazide.Approved
PonatinibThe serum concentration of Indacaterol can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Indacaterol can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrasteroneIndacaterol may increase the hypokalemic activities of Prasterone.Approved, Nutraceutical
PravastatinThe serum concentration of Indacaterol can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Indacaterol can be increased when it is combined with Prazosin.Approved
PrednicarbateIndacaterol may increase the hypokalemic activities of Prednicarbate.Approved
PrednisoloneIndacaterol may increase the hypokalemic activities of Prednisolone.Approved, Vet Approved
PrednisoneIndacaterol may increase the hypokalemic activities of Prednisone.Approved, Vet Approved
PregnenoloneIndacaterol may increase the hypokalemic activities of Pregnenolone.Experimental
PrimaquineIndacaterol may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Indacaterol can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Indacaterol can be increased when it is combined with Probenecid.Approved
ProcainamideIndacaterol may increase the QTc-prolonging activities of Procainamide.Approved
ProgesteroneThe serum concentration of Indacaterol can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineIndacaterol may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Indacaterol can be increased when it is combined with Promethazine.Approved
PropafenoneIndacaterol may increase the QTc-prolonging activities of Propafenone.Approved
PropranololPropranolol may decrease the bronchodilatory activities of Indacaterol.Approved, Investigational
ProtriptylineThe serum concentration of Indacaterol can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Indacaterol can be increased when it is combined with Quercetin.Experimental
QuetiapineIndacaterol may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Indacaterol can be increased when it is combined with Quinacrine.Approved
QuinethazoneIndacaterol may increase the hypokalemic activities of Quinethazone.Approved
QuinidineIndacaterol may increase the QTc-prolonging activities of Quinidine.Approved
QuinineIndacaterol may increase the QTc-prolonging activities of Quinine.Approved
RanitidineThe serum concentration of Indacaterol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Indacaterol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Indacaterol.Approved
ReboxetineThe serum concentration of Indacaterol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Indacaterol can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Indacaterol can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Indacaterol can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Indacaterol can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Indacaterol can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Indacaterol can be increased when it is combined with Rilpivirine.Approved
RimexoloneIndacaterol may increase the hypokalemic activities of Rimexolone.Approved
RitonavirThe metabolism of Indacaterol can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Indacaterol can be increased when it is combined with Rolapitant.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Indacaterol.Withdrawn
SaquinavirThe metabolism of Indacaterol can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Indacaterol can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Indacaterol can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Indacaterol can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Indacaterol can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Indacaterol can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Indacaterol can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Indacaterol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Indacaterol can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Indacaterol can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolSotalol may decrease the bronchodilatory activities of Indacaterol.Approved
SpironolactoneThe serum concentration of Indacaterol can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Indacaterol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Indacaterol can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Indacaterol can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Indacaterol can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Indacaterol can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleIndacaterol may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Indacaterol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Indacaterol can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Indacaterol can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Indacaterol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Indacaterol can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Indacaterol can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe metabolism of Indacaterol can be decreased when combined with Telaprevir.Approved
TelavancinIndacaterol may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Indacaterol can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Indacaterol can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Indacaterol can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Indacaterol can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Indacaterol can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Indacaterol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Indacaterol can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineIndacaterol may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe risk or severity of adverse effects can be increased when Theophylline is combined with Indacaterol.Approved
ThioridazineIndacaterol may increase the QTc-prolonging activities of Thioridazine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Indacaterol.Approved
TicagrelorThe serum concentration of Indacaterol can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Indacaterol can be decreased when combined with Ticlopidine.Approved
TimololTimolol may decrease the bronchodilatory activities of Indacaterol.Approved
TixocortolIndacaterol may increase the hypokalemic activities of Tixocortol.Approved
TocilizumabThe serum concentration of Indacaterol can be decreased when it is combined with Tocilizumab.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Indacaterol.Approved
TolvaptanThe serum concentration of Indacaterol can be increased when it is combined with Tolvaptan.Approved
TorasemideIndacaterol may increase the hypokalemic activities of Torasemide.Approved
ToremifeneIndacaterol may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Indacaterol.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Indacaterol.Approved
TrazodoneThe serum concentration of Indacaterol can be decreased when it is combined with Trazodone.Approved, Investigational
TriamcinoloneIndacaterol may increase the hypokalemic activities of Triamcinolone.Approved, Vet Approved
TrichlormethiazideIndacaterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Indacaterol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Indacaterol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Indacaterol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Indacaterol can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Indacaterol can be increased when it is combined with Troleandomycin.Approved
VandetanibIndacaterol may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibIndacaterol may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Indacaterol can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Indacaterol can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Indacaterol can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Indacaterol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Indacaterol can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Indacaterol can be decreased when combined with Voriconazole.Approved, Investigational
ZimelidineThe serum concentration of Indacaterol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneIndacaterol may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolIndacaterol may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M: Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. 2007 Mar;29(3):575-81. Epub 2006 Nov 29. [PubMed:17135231 ]
  2. Kagan M, Dain J, Peng L, Reynolds C: Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos. 2012 Sep;40(9):1712-22. doi: 10.1124/dmd.112.046151. Epub 2012 May 30. [PubMed:22648561 ]
  3. Reid DJ, Pham NT: Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15. doi: 10.4137/CCRPM.S8140. Print 2013. [PubMed:23641160 ]
External Links
ATC CodesR03AL04R03AC18
AHFS Codes
  • 12:12.08.12
PDB EntriesNot Available
FDA labelDownload (360 KB)
MSDSDownload (479 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9963
Blood Brain Barrier+0.5
Caco-2 permeable-0.6288
P-glycoprotein substrateSubstrate0.6953
P-glycoprotein inhibitor INon-inhibitor0.9284
P-glycoprotein inhibitor IINon-inhibitor0.9178
Renal organic cation transporterNon-inhibitor0.8838
CYP450 2C9 substrateNon-substrate0.8148
CYP450 2D6 substrateNon-substrate0.6907
CYP450 3A4 substrateSubstrate0.5896
CYP450 1A2 substrateInhibitor0.553
CYP450 2C9 inhibitorNon-inhibitor0.56
CYP450 2D6 inhibitorNon-inhibitor0.8547
CYP450 2C19 inhibitorNon-inhibitor0.5581
CYP450 3A4 inhibitorNon-inhibitor0.6546
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5888
Ames testNon AMES toxic0.7577
CarcinogenicityNon-carcinogens0.8559
BiodegradationNot ready biodegradable0.9856
Rat acute toxicity2.6531 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9657
hERG inhibition (predictor II)Inhibitor0.6406
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral; Respiratory (inhalation)75 ug/1
CapsuleRespiratory (inhalation)75 mcg
CapsuleRespiratory (inhalation)150 μg
CapsuleRespiratory (inhalation)300 μg
Capsule; kitRespiratory (inhalation)
CapsuleRespiratory (inhalation)
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6521260 No1996-01-312016-01-31Us
US6582678 No1998-04-242018-04-24Us
US6878721 No2000-10-102020-10-10Us
US7229607 No2001-04-092021-04-09Us
US7736670 No2001-06-272021-06-27Us
US7820694 No2000-06-022020-06-02Us
US8029768 No2001-04-092021-04-09Us
US8048451 No2001-06-272021-06-27Us
US8067437 No2000-06-022020-06-02Us
US8182838 No2008-10-202028-10-20Us
US8283362 No2000-06-022020-06-02Us
US8303991 No2001-06-272021-06-27Us
US8435567 No2001-06-272021-06-27Us
US8479730 No2008-10-112028-10-11Us
US8580306 No2001-06-272021-06-27Us
US8658673 No2000-06-022020-06-02Us
US8796307 No2000-06-022020-06-02Us
US8956661 No2001-06-272021-06-27Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point195-202°C with decompositionNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00798 mg/mLALOGPS
logP3.31ALOGPS
logP3.26ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)8.51ChemAxon
pKa (Strongest Basic)9.71ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area81.59 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity118.1 m3·mol-1ChemAxon
Polarizability44.96 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydroxyquinolones. These are compounds containing a quinoline moiety bearing a hydroxyl group and a ketone. Quinoline or benzo[b]pyridine is a bicyclic compound that consists of benzene fused to a pyridine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassQuinolones and derivatives
Direct ParentHydroxyquinolones
Alternative Parents
Substituents
  • Hydroxyquinolone
  • 8-hydroxyquinoline
  • Hydroxyquinoline
  • Dihydroquinolone
  • Dihydroquinoline
  • Indane
  • Aralkylamine
  • Pyridinone
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Secondary alcohol
  • Lactam
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Cazzola M, Matera MG, Lotvall J: Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2005 Jul;14(7):775-83. [PubMed:16022567 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on December 04, 2016 02:45